3 Great Reasons Why GlaxoSmithKline plc Is Set To Take Off

Royston Wild looks at the major share price drivers for GlaxoSmithKline plc (LON: GSK).

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Today I am looking at why I believe GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) is the right tonic for investors seeking bumper returns from their invested cash.

Bubbly pipeline yielding exciting growth opps

Like many giants across the pharma space, GlaxoSmithKline has suffered heavily for several years now from the patent expiration for many of its key drugs. But the company has been vigilant in developing its pipeline to offset this and drive future earnings growth.

Indeed, the firm has received US approval for its Breo Ellipta, Tafinlar and Mekinist drugs in recent months, and is expected to receive Phase III testing data for around a dozen or so more potential earnings drivers during 2013.

And GlaxoSmithKline’s latest budding earnings generator received US Food and Drug Administration (FDA) approval just last month. Tivicay — developed by its ViiV Healthcare joint venture — is an integrase inhibitor used to block the spread of the HIV virus, and is used alongside other antiretroviral agents for the treatment of HIV-1. A Reuters study showed sales of the drug could reach $900m by 2017.

An active M&A player

To complement the heavy investment it has ploughed into R&D, GlaxoSmithKline remains a shrewd operator on the acquisition front and last month affirmed its commitment to conclude value-accretive bolt-on purchases through its substantial cash pile.

Recent purchases include Swiss vaccine development specialist Okairos in May for £214m, a move that will give the company access to cutting-edge technology to boost its vaccine offerings. And GlaxoSmithKline is not afraid to embark on mammoth game-changing deals, its $3bn purchase of Human Genome Sciences last August giving it total control of the Benlysta lupus treatment.

A dependable dividend deliverer

This pharmaceutical play is a smart selection for those seeking chubby, and increasingly-generous, dividend income. GlaxoSmithKline has steadily increased the full-year payout in recent years, even during times of severe earnings pressure, and total payouts have risen 30% over the past five years, hitting 74p per share in 2012.

And City analysts expect last year’s dividend to increase to 77.4p and 82p per share in 2013 and 2014 respectively, via healthy rises of 5% and 6%. And these prospective payments currently carry yields of 4.6% and 4.9% respectively.

These yields compare extremely favourable with an average forward payment of 2.4% for the pharmaceuticals and biotechnology sector, and 3.2% for the FTSE 100.

The right tonic for stunning shareholder returns

I reckon that GlaxoSmithKline is the right prescription for  savvy investors seeking strong earnings potential. And if you are looking for a whole host of other FTSE 100 winners to bolster your investment returns, I strongly recommend you check out these recommendations from veteran fund manager Neil Woodford.

Woodford — in charge of UK Equities at Invesco Perpetual — has more than 30 years’ experience in the industry, and has marked out two other fantastic pharmaceutical giants ready to generate monumental gains.

This exclusive report, compiled by The Motley Fool’s crack team of analysts, is totally free and comes with no further obligation. Click here now to download your copy.

> Royston does not own shares in GlaxoSmithKline. The Motley Fool has recommended GlaxoSmithKline.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

More on Investing Articles

2024 year number handwritten on a sandy beach at sunrise
Investing Articles

Here’s my plan to make the most of juicy UK shares ahead of 2024 and beyond!

Our writer reckons there hasn't been a better time to snap up quality UK shares. She explains how she's planning…

Read more »

Young Black woman using a debit card at an ATM to withdraw money
Investing Articles

Here’s how many Lloyds shares I’d need to buy for a £100 monthly income!

Offering a higher dividend yield than the average across FTSE 100 stocks, are Lloyds shares worth buying for passive income…

Read more »

Playful senior couple in aprons dancing and smiling while preparing healthy dinner at home
Investing Articles

Up 27% in 2023, what next for the Tesco share price in 2024?

The Tesco share price has had a great 2023, rising 27% while the FTSE 100 was flat. But what might…

Read more »

Hand is turning a dice and changes the direction of an arrow symbolizing that the value of an ETF (Exchange Traded Fund) is going up (or vice versa)
Investing Articles

FTSE 250? No, I’d buy this index fund instead

Investing in index funds can be a profitable enterprise. Our author has been exploring the different options to determine the…

Read more »

Young black colleagues high-fiving each other at work
Investing Articles

This 4% yielding FTSE 100 giant is dirt-cheap and perfect for passive income!

Looking for a mammoth business with shares trading at discount levels and offering an excellent passive income opportunity? Our writer…

Read more »

UK money in a Jar on a background
Investing Articles

Here’s how I’d use dividend shares to try and turn £5,000 of savings into passive income of £900 a year

With dividend shares at today’s prices, Stephen Wright thinks there are two ways to turn a £5,000 investment into something…

Read more »

Investing Articles

After a recovery that Lazarus would have been proud of, is the easyJet share price worth a look?

With its dividend restored and its balance sheet repaired, the easyJet share price looks like a bargain. But Stephen Wright…

Read more »

Photo of a man going through financial problems
Investing Articles

Are Rolls-Royce shares REALLY about to pay a dividend?

Rolls-Royce shares are expected to start paying dividends in the near future. But how realistic are the company's current forecasts?

Read more »